endpts.com·Jun 10, 2026
Novartis has expanded its partnership with Orionis Biosciences by entering into a second molecular glue deal valued at $40 million upfront, with potential further payments totaling up to $1.4 billion.
Novartis' decision to deepen its collaboration with Orionis Biosciences, marked by a $40 million upfront investment, signals a strong endorsement of molecular glue technology's potential in drug discovery. This partnership highlights an actionable investment opportunity for those tracking advancements in targeted protein degradation, a promising area within biotech that could disrupt traditional drug development pathways.